Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields

Tiffanie S. Stewart; Abhignyan Nagesetti; Rakesh Guduru; Ping Liang; Emmanuel Stimphil; Ali Hadjikhani; Luis Salgueiro; Jeffrey Horstmyer; Renzhi Cai; Andrew Schally; Sakhrat Khizroev

doi:10.2217/nnm-2017-0300

Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields

Tiffanie S. Stewart, Abhignyan Nagesetti, Rakesh Guduru, Ping Liang, Emmanuel Stimphil, Ali Hadjikhani, Luis Salgueiro, Jeffrey Horstmyer, Renzhi Cai, Andrew Schally, Sakhrat Khizroev

Pathology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Aim: We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas. Methods: Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe₂O₄@BaTiO₃. Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs. In vitro experiments utilized human glioblastoma cells (U-87MG) and human brain microvascular endothelial cells. Results: The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively. Conclusion: The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.

Original language	English (US)
Pages (from-to)	423-438
Number of pages	16
Journal	Nanomedicine
Volume	13
Issue number	4
DOIs	https://doi.org/10.2217/nnm-2017-0300
State	Published - Feb 2018

Keywords

cancer/oncology
gene/drug delivery
nanoparticles

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
Materials Science(all)

Access to Document

10.2217/nnm-2017-0300

Cite this

@article{119af5bce63943e786e94a9fb60d5370,

title = "Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields",

abstract = "Aim: We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas. Methods: Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3. Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs. In vitro experiments utilized human glioblastoma cells (U-87MG) and human brain microvascular endothelial cells. Results: The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively. Conclusion: The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.",

keywords = "cancer/oncology, gene/drug delivery, nanoparticles",

author = "Stewart, {Tiffanie S.} and Abhignyan Nagesetti and Rakesh Guduru and Ping Liang and Emmanuel Stimphil and Ali Hadjikhani and Luis Salgueiro and Jeffrey Horstmyer and Renzhi Cai and Andrew Schally and Sakhrat Khizroev",

note = "Funding Information: The authors acknowledge partial financial support from National Science Foundation (NSF) awards # ECCS-1408063, ECCS-0939514 and IIP-1237818, National Institute of Health (NIH) DA # R01DA034547–01, and Neuroscience Centers of Florida Foundation (NSCFF). The authors have no other relevant affiliations of financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2018 2018 Future Medicine Ltd.",

year = "2018",

month = feb,

doi = "10.2217/nnm-2017-0300",

language = "English (US)",

volume = "13",

pages = "423--438",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "4",

}

TY - JOUR

T1 - Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields

AU - Stewart, Tiffanie S.

AU - Nagesetti, Abhignyan

AU - Guduru, Rakesh

AU - Liang, Ping

AU - Stimphil, Emmanuel

AU - Hadjikhani, Ali

AU - Salgueiro, Luis

AU - Horstmyer, Jeffrey

AU - Cai, Renzhi

AU - Schally, Andrew

AU - Khizroev, Sakhrat

N1 - Funding Information: The authors acknowledge partial financial support from National Science Foundation (NSF) awards # ECCS-1408063, ECCS-0939514 and IIP-1237818, National Institute of Health (NIH) DA # R01DA034547–01, and Neuroscience Centers of Florida Foundation (NSCFF). The authors have no other relevant affiliations of financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2018 2018 Future Medicine Ltd.

PY - 2018/2

Y1 - 2018/2

N2 - Aim: We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas. Methods: Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3. Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs. In vitro experiments utilized human glioblastoma cells (U-87MG) and human brain microvascular endothelial cells. Results: The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively. Conclusion: The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.

AB - Aim: We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas. Methods: Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3. Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs. In vitro experiments utilized human glioblastoma cells (U-87MG) and human brain microvascular endothelial cells. Results: The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively. Conclusion: The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.

KW - cancer/oncology

KW - gene/drug delivery

KW - nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85041600670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041600670&partnerID=8YFLogxK

U2 - 10.2217/nnm-2017-0300

DO - 10.2217/nnm-2017-0300

M3 - Article

C2 - 29345190

AN - SCOPUS:85041600670

VL - 13

SP - 423

EP - 438

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 4

ER -

Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this